Acarix A/S is based on pioneering research performed at the Aalborg University, Denmark, initiated in 2004. The research group received the award, ‘MedicoPrisen’, from Medicoindustrien (Danish Medtech trade association) in 2007. A research and development collaboration was established in 2007 between Aalborg University and Coloplast A/S, receiving public support from the Danish National Advanced Technology Foundation in 2008.
Acarix was established in 2009 as a spin-out from Coloplast A/S, and since 2010 investors SEED Capital (DK) and Sunstone Life Science Ventures (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016.
Acarix can be reached by email at firstname.lastname@example.org for general questions or information.
Requests for information on the company, financial or clinical/technical issues can also be forwarded directly to CEO Søren Rysholt Christiansen, CFO Christian Lindholm or COO Claus Bo Vöge Christensen respectively.
We try to answer promptly and within 24 hours.
Our Management Team